Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2HER-2 Gene Amplification 1

Interventions

pembrolizumab 305Paclitaxel 205Carboplatin 201Gemcitabine 173Cisplatin 140Docetaxel 138Cyclophosphamide 137Nivolumab 129Bevacizumab 118Injections 112fludarabine 97atezolizumab 91Pemetrexed 91Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Midazolam 55Lenalidomide 55Ipilimumab 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × MM-111 × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

NCT00911898 2015-01-13

Monotherapy

Merrimack Pharmaceuticals

Phase 1 Completed
20 enrolled 5 charts
Breast

Breast Neoplasms

NCT01097460 2015-01-07

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
16 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡